Suppr超能文献

Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.

作者信息

Kneer J, Tam Y K, Blouin R A, Frey F J, Keller E, Stathakis C, Luginbuehl B, Stoeckel K

机构信息

Department of Clinical Research, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

出版信息

Antimicrob Agents Chemother. 1989 Nov;33(11):1952-7. doi: 10.1128/AAC.33.11.1952.

Abstract

The pharmacokinetics of cefetamet after a short intravenous infusion of cefetamet (515 mg) and oral administration of 1,000 mg of cefetamet pivoxil were studied in 9 healthy subjects and in 38 patients with various degrees of renal impairment. The results showed that cefetamet elimination was dependent on renal function. After intravenous dosing, total body (CLS), renal (CLR), and nonrenal (CLNR) clearances were linearly related to creatinine clearance (CLCR; r = 0.95, 0.92, and 0.59, respectively). Elimination half-life (t1/2 beta) was prolonged from 2.46 +/- 0.33 h in normal subjects to 29.1 +/- 13.9 h in patients with CLCR of less than 10 ml/min per 1.73 m2. Correspondingly, CLS and CLR decreased from 1.77 +/- 0.27 and 1.42 +/- 0.25 ml/min per kg to 0.14 +/- 0.04 and 0.04 +/- 0.03 ml/min per kg, respectively. The volume of distribution at steady state (0.298 +/- 0.049 liter/kg) for cefetamet was not altered by renal insufficiency (P greater than 0.05). After oral administration, the elimination parameters, t1/2 beta and CLR, were insignificantly different from the intravenous data (P greater than 0.05). Furthermore, the bioavailability (F) of cefetamet pivoxil (45 +/- 13%) was not altered by renal failure (P greater than 0.05). However, maximum concentration in plasma and the time to achieve this value were significantly increased (5.86 +/- 0.74 versus 14.8 +/- 6.14 micrograms/ml and 3.9 +/- 1.1 versus 8.4 +/- 1.7 h, respectively; P less than 0.05). Based on these observations, it is recommended that patients with CLcr of <10 ml/min per 1.73 m2 and between 10 and 39 ml/min per 1.73 m2 be given one-quarter of the normal daily dose either once or twice daily. Patients with CLcr between 40 and 80 ml/min per 1.73 m2 should receive one-half of the normal dose twice daily. For patients with CLcr of <10 ml/min per 1.73 m2, it would be recommended that they receive a normal standard dose as a loading dose on day 1 of treatment.

摘要

相似文献

1
Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.
Antimicrob Agents Chemother. 1989 Nov;33(11):1952-7. doi: 10.1128/AAC.33.11.1952.
3
Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis.
Antimicrob Agents Chemother. 1990 Jul;34(7):1318-22. doi: 10.1128/AAC.34.7.1318.
5
Cefetamet pivoxil clinical pharmacokinetics.
Clin Pharmacokinet. 1993 Sep;25(3):172-88. doi: 10.2165/00003088-199325030-00002.
6
Influence of antacid and ranitidine on the pharmacokinetics of oral cefetamet pivoxil.
Antimicrob Agents Chemother. 1990 Sep;34(9):1744-8. doi: 10.1128/AAC.34.9.1744.
8
Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in children.
Antimicrob Agents Chemother. 1991 Apr;35(4):720-5. doi: 10.1128/AAC.35.4.720.
9
Pharmacokinetics of cefetamet pivoxil (Ro 15-8075) with ascending oral doses in normal healthy volunteers.
Antimicrob Agents Chemother. 1989 Jun;33(6):957-9. doi: 10.1128/AAC.33.6.957.
10
Influence of maturation and growth on cefetamet pivoxil pharmacokinetics: rational dosing for infants.
Antimicrob Agents Chemother. 1996 Mar;40(3):567-74. doi: 10.1128/AAC.40.3.567.

引用本文的文献

2
Pharmacokinetics and pharmacodynamics of oral and intravenous cefetamet in dog.
Eur J Drug Metab Pharmacokinet. 2015 Dec;40(4):401-7. doi: 10.1007/s13318-014-0217-6. Epub 2014 Jul 13.
3
Cefetamet pivoxil clinical pharmacokinetics.
Clin Pharmacokinet. 1993 Sep;25(3):172-88. doi: 10.2165/00003088-199325030-00002.
5
Clinical pharmacokinetics of newer cephalosporins.
Clin Pharmacokinet. 1995 May;28(5):361-84. doi: 10.2165/00003088-199528050-00003.
6
Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis.
Antimicrob Agents Chemother. 1990 Jul;34(7):1318-22. doi: 10.1128/AAC.34.7.1318.
7
Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in children.
Antimicrob Agents Chemother. 1991 Apr;35(4):720-5. doi: 10.1128/AAC.35.4.720.
8
Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.
Antimicrob Agents Chemother. 1992 Jan;36(1):126-31. doi: 10.1128/AAC.36.1.126.
9
Considerations in dosage selection for third generation cephalosporins.
Clin Pharmacokinet. 1992 Feb;22(2):132-43. doi: 10.2165/00003088-199222020-00004.
10
Future directions in antimicrobial chemotherapy.
Pharm Weekbl Sci. 1992 Aug 21;14(4A):229-44. doi: 10.1007/BF01962545.

本文引用的文献

1
Concepts basic to pharmacokinetics.
Pharmacol Ther. 1981;12(1):109-31. doi: 10.1016/0163-7258(81)90077-2.
2
Cefsulodin kinetics in renal impairment.
Clin Pharmacol Ther. 1982 May;31(5):602-8. doi: 10.1038/clpt.1982.84.
3
Single-dose ceftriaxone kinetics in functionally anephric patients.
Clin Pharmacol Ther. 1983 May;33(5):633-41. doi: 10.1038/clpt.1983.86.
5
Clinical pharmacokinetics of the third generation cephalosporins.
Clin Pharmacokinet. 1985 Mar-Apr;10(2):101-43. doi: 10.2165/00003088-198510020-00001.
6
Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency.
Antimicrob Agents Chemother. 1986 Sep;30(3):485-90. doi: 10.1128/AAC.30.3.485.
7
In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites.
Antimicrob Agents Chemother. 1986 Jun;29(6):1067-72. doi: 10.1128/AAC.29.6.1067.
8
Pharmacokinetics of carumonam in patients with renal insufficiency.
Antimicrob Agents Chemother. 1986 Jan;29(1):116-21. doi: 10.1128/AAC.29.1.116.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验